Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11902929 | 0.83 | TAS1R3 (0.33) | MAPTACLYALDH1A1MEP1BTAS1R3 | |
| SCHEMBL1610274 | 0.82 | ALDH1A1 (0.42) | MAPTKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL11902557 | 0.81 | MEP1B (0.34) | MAPTACLYALDH1A1MEP1BTAS1R3 | |
| SCHEMBL11903154 | 0.79 | ACLY (0.34) | MAPTACLYALDH1A1MEP1BTAS1R3 | |
| SCHEMBL117789 | 0.78 | TAS1R3 (0.40) | KMT2AACLYALDH1A1MEP1BTAS1R3 | |
| SCHEMBL11902763 | 0.78 | ACLY (0.34) | MAPTACLYALDH1A1MEP1BTAS1R3 | |
| SCHEMBL716664 | 0.76 | TAS1R3 (0.38) | ACLYALDH1A1MEP1BTAS1R3TAS1R1 | |
| SCHEMBL1114950 | 0.76 | TAS1R3 (0.38) | ACLYALDH1A1MEP1BTAS1R3TAS1R1 | |
| SCHEMBL1654721 | 0.76 | CYP1A2 (0.43) | MAPTKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL29769728 | 0.75 | KDM4E (0.38) | ACLYALDH1A1MEP1BTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009081112-A2 | CHEMICAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086759-A1 | CHEMICAL COMPOUNDS | DDT, PNPO, CBR3 | MAPT 2800/4885KMT2A 2003/4885MEN1 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.